Navigation Links
CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
Date:6/25/2008

BRANFORD, Conn., June 25 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today the treatment of the first patient in its CR011-vcMMAE Phase II breast cancer study.

The Phase II trial is an open-label, multi-center study of CR011-vcMMAE administered intravenously once every three weeks to patients with locally-advanced or metastatic breast cancer who have received prior therapy. This study will enroll up to approximately 40 patients to confirm the maximum tolerated dose (MTD) in this population and to assess efficacy using a Simon 2-Stage design with an endpoint of progression-free rate at 12 weeks. The principal investigator is Dr. Linda Vahdat, Medical Director of the Breast Cancer Research Program and Associate Professor of Clinical Medicine, NewYork-Presbyterian Hospital/Weill Cornell.

"We believe that GPNMB is a promising target in breast cancer, and we look forward to better understanding how CR011-vcMMAE could be used in the treatment of this disease," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "We are confident in our ability to continue the rapid development of this program and look forward to providing updated CR011-vcMMAE results for the treatment of melanoma by the end of 2008 and the presentation of preliminary results from this newly initiated study in breast cancer during the first half of 2009."

CR011-vcMMAE targets a protein known as glycoprotein NMB (GPNMB), which is overexpressed in a variety of cancers including breast cancer, melanoma, and brain tumors. CR011-vcMMAE is an antibody-drug conjugate comprised of a fully-human monoclonal antibody against GPNMB linked
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Research and Markets has announced ... report to their offering. Animal vaccines ... Animal vaccines are generally prepared from weakened or dead microbes ... state. Some of the animal vaccines are also formulated using ... or toxic components. These components act as ...
(Date:9/16/2014)... 16, 2014  Denovo Biopharma, LLC, today announced ... drug, from Eli Lilly and Company (NYSE:  LLY). ... commercialize enzastaurin globally, including transfer of all intellectual ... Lilly developed enzastaurin in a variety ... 3 clinical trials for diffuse large B-cell lymphoma ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011  GP Strategies Corporation (NYSE: GPX ), ... GP Strategies Corporation with and into its ... company structure. General Physics, which is the sole operating ... corporation and will be renamed GP Strategies Corporation when ...
... BOWIE, Md., Dec. 15, 2011  MedAssurant, Inc., ... today announced that Healthcare Partners, IPA (HCPIPA), ... associations (IPA) in the Northeast, has selected ... (CARA™)  solutions to proactively identify gaps in ...
Cached Medicine Technology:GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 2GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 3Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3
(Date:9/16/2014)... 16, 2014 Holganix, an elite member ... growing companies in the country, produces an organic Bionutritional ... health-care by naturally decreasing disease and insect damage though ... that it will hold its third annual Bionutritional Summit ... 22, 2014 from 1:00 P.M. through 6:00 P.M., the ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous ... one shoulder evening gown collection. According to the company’s ... discounted rates (up to 69% off) at present. Additionally, all ... , “I am a frequent caller of your site. I ... dress, I feel quite happy. All items are of good ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... These new programs allow those who haven’t owned a home ... in a 0% interest free, 2nd down payment assistance mortgage ... programs, are listed on their private website. The $10,000 does ... move out of the property. The down payment assistance 2nd ... monthly payments paid by the Borrower. The money is paid ...
(Date:9/16/2014)... September 14, 2014 A new study ... branch (SB) stenting of true coronary bifurcation lesions ... care. The DKCRUSH-VI clinical trial is the first ... , Findings were reported today at the 26th ... by the Cardiovascular Research Foundation (CRF), TCT is ...
Breaking Medicine News(10 mins):Health News:Holganix Holds 3rd Annual Bionutrional Summit in Louisville, Kentucky 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2
... Justice Department,today announced that it has reached a ... headquartered in Southfield, Mich., under the,Americans with Disabilities ... Clinic refused to serve a prospective client because ... today,s agreement, Medical Weight Loss Clinic will,provide training ...
... more than 40 percent of widowers in that country whose ... they were either never told that their spouse,s cancer was ... of her life. Eighty-six percent of widowers believed next-of-kin should ... 71 percent of the men who did not recall being ...
... Preventive Medicine, (http://www.USPreventiveMedicine.com ) the leader in disease ... its campaign to make the,United States a healthier ... Pediatrics, which this week called for children to ... the "Healthiest Nation Campaign," a program aimed,at placing ...
... in Oxygen Orders, Lack of,Trained Technicians, ARLINGTON, ... program for durable medical equipment has created,concern and ... medical equipment providers across the country since it,was ... The bidding program has triggered widespread disruptions ...
... Chicago is one of 11 centers in the United ... Clinical Islet Transplant Consortium funded by the National Institutes ... to test new approaches to islet transplantation that may ... adults with difficult-to-control type 1 diabetes. , Patients with ...
... team will give the men we serve a distinct advantage on, ... ... Directors, DETROIT, July 8 The Mariners Inn shelter ... executive officer and David Sampson as chief operating officer., "Both Jim and ...
Cached Medicine News:Health News:Justice Department Reaches Settlement Agreement With Medical Weight Loss Clinic 2Health News:Study finds that significant proportion of men told wife's cancer was incurable late or not at all 2Health News:U.S. Preventive Medicine Applauds Leading Health Organizations for Disease Prevention Platforms 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 4Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 5Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:Mariners Inn Announces New Executive Leadership 2
The GII titanium anchor with nitinol arcs is used for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor used by...
... greater definition than a standard Galilean ... The Hi-Res five element system provides ... lightweight system., ,Order frame separately., ,Keeler ... in a soft carrying case and ...
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
... Wristrest has become an important standard in busy ... encircles the patient's head and supports arms and ... easy draping especially when fluids are collected. The ... way for easy patient transfer on and off ...
Medicine Products: